Brain Tumours

Results

• Phase 1 portion completed – N = 27 patients – May 2013 to November 2014 • Clinical data cut 7 March 2015 • Duration on study from 9 weeks to 23 months (ongoing) • 20 of 27 patients remain on dabrafenib

112